Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Omega-3 Supplementation for Children With Language Impairments

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children in the chronological age range of 24 to 42 months at the time of initial assessment~* diagnosis of expressive, receptive or mixed language impairment (LI) by a certified Speech-Language Pathologist (S-LP)~* ability to take daily omega-3 supplementation (with caregiver assistance)~Exclusion Criteria:~* children with any organic disease processes or genetic syndromes, or known developmental disorders such as autism that may present with language impairment~* children with hearing impairment~* children who take any non-standard dietary supplements (i.e., apart from multi-vitamins), particularly any omega-3 FA, prior to starting the study~* children whose parents do not have an adequate understanding of English or French

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 42 Months
- Healthy Volunteers: f

Study Arms:
- Omega-3 (Type: EXPERIMENTAL): Treatment arm, using the omega-3 product (fish oil/paste)
- Control (Type: PLACEBO_COMPARATOR): Placebo is a paste of non-omega-3 (plant based) oil with a taste/flavour identical to intervention paste

Based on this trial design, predict the completion outcome and termination type (if applicable).